Prats CI, López de Ayala CE, Herranz PP, Arranz SDM, Corral LM, Casado JM

Language: Spanish
References: 6
Page: 171-174
PDF size: 346.98 Kb.

ABSTRACT

Vitiligo is an acquired, idiopathic disorder characterized by depigmented macules which involves an obvious cosmetic, social and psicological repercussion. Current treatment modalities for the management of vitiligo are multiple but, unfortunatelly, most of cases achieve inconsistent and incomplete responses. Recently, new pharmacolgical agents have been investigated like Tacrolimus. They are more selective, powerful, and with no local adverse side effects. For that reason, these immunosuppressive agents might be an effective therapy for imflamatory skin disorders such as vitiligo. We report our preliminary clinical experience in the managmeent of vitiligo with topical Tacrolimus ointment. We describe three patients with vitiligo affecting the face in two of them, and the face and back of hands in the latest. Tacrolimus 0,1% ointment was applied, twice-daily, in conjuntion with natural sunlight exposure after the application, during fifteen minutes. After several months of treatment, two patients developed complete repigmentation of the face, with no response on back of hands, in one of them. The latest showed a noticeable follicular repigmentation. Repigmentation persists after several months after finishing the therapy. None of the patients had any local adverse effects. In conclusion, Tacrolimus ointment could be a rapidly, efficacious, and safe option for the treatment of vitiligo.Despite the good results achieved by our patients, larger studies that are double-blinded and placebo controlled would be helpful to prove the efficacy of topical tacrolimus in the treatment of vitiligo.

REFERENCES

1. Olsson MJ, Juhlin L. Long-term follow-up of leucoderma patients treated with transplants of autologous cultured melanocytes, ultrathin epidermal sheets and basal cell layer suspension. Br J Dermatol 2002;147: 893-904.

2. Njoo MD, Spuls PI, Bos JD, Westerhof W, et al. Nonsurgical repigmenation therapies in vitiligo. Arch Dermatol 1998;134:1532-40. 3. Cui J, Harning R, Henn M, Bystryn JC. Identification of pigment cell antigens defined by vitiligo antibodies. J Invest Dermatol 1992;98:162-5.

3. Ahn SK, Choi EH, Lee SH, Won JH, et al. Immunohistochemical studies from vitiligo: comparison between active and inactive lesions. Yonsei Med J 1994;35:404-10. 5. Kino T, Hatanaka H, Miyata S, et al. FK-506, a novel immunosuppressant isolated from a Streptomyces, II: immunosuppressive effect of FK-506 in vitro. J Antibiot 1987;40:1256-65.

4. Gupta AK, Adamiak A, Chow M. Tacrolimus: a review of its use for the management of dermatoses. J Eur Acad Dermatol Venereo 2002;16:100 -14.

5. Grimes PE, Soriano T, Dytoc MT. Topical tacrolimus for repigmentation of vitiligo. J Am Acad Dermatol 2002;47:789-91. 8. H. Plettenberg, T. Assmann, T. Ruzicka. Childhood vitiligo and Tacrolimus. Arch Dermatol 2003;139:651-4.

6. Lisa B, Travis BS, Jeffrey M, Weinberg MD, et al. Succesful treatment of vitiligo with 0.1% tacrolimus ointment. Arch Dermatol 2003;139:571-4.